Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at... | June 16, 2023
Source: marketscreener.com